Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 96
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Am J Gastroenterol ; 119(7): 1365-1372, 2024 07 01.
Artículo en Inglés | MEDLINE | ID: mdl-38131615

RESUMEN

INTRODUCTION: Intravenous corticosteroids are the mainstay of treatment of patients hospitalized with acute severe ulcerative colitis (ASUC). However, 30%-40% of the patients are refractory to corticosteroids. We investigated whether addition of tofacitinib to corticosteroids improved the treatment responsiveness in patients with ASUC. METHODS: This single-center, double-blind, placebo-controlled trial randomized adult patients with ASUC (defined by the Truelove Witts severity criteria) to receive either tofacitinib (10 mg thrice daily) or a matching placebo for 7 days while continuing intravenous corticosteroids (hydrocortisone 100 mg every 6 hours). The primary end point was response to treatment (decline in the Lichtiger index by >3 points and an absolute score <10 for 2 consecutive days without the need for rescue therapy) by day 7. The key secondary outcome was the cumulative probability of requiring initiation of infliximab or undergoing colectomy within 90 days following randomization. All analyses were performed in the intention-to-treat population. RESULTS: A total of 104 patients were randomly assigned to a treatment group (53 to tofacitinib and 51 to placebo). At day 7, response to treatment was achieved in 44/53 (83.01%) patients receiving tofacitinib vs 30/51 (58.82%) patients receiving placebo (odds ratio 3.42, 95% confidence interval 1.37-8.48, P = 0.007). The need for rescue therapy by day 7 was lower in the tofacitinib arm (odds ratio 0.27, 95% confidence interval 0.09-0.78, P = 0.01). The cumulative probability of need for rescue therapy at day 90 was 0.13 in patients who received tofacitinib vs 0.38 in patients receiving placebo (log-rank P = 0.003). Most of the treatment-related adverse effects were mild. One patient, receiving tofacitinib, developed dural venous sinus thrombosis. DISCUSSION: In patients with ASUC, combination of tofacitinib and corticosteroids improved treatment responsiveness and decreased the need for rescue therapy.


Asunto(s)
Colitis Ulcerosa , Piperidinas , Pirimidinas , Pirroles , Humanos , Piperidinas/uso terapéutico , Colitis Ulcerosa/tratamiento farmacológico , Pirimidinas/uso terapéutico , Masculino , Femenino , Método Doble Ciego , Adulto , Pirroles/uso terapéutico , Pirroles/administración & dosificación , Persona de Mediana Edad , Enfermedad Aguda , Resultado del Tratamiento , Índice de Severidad de la Enfermedad , Quimioterapia Combinada , Inhibidores de Proteínas Quinasas/uso terapéutico , Colectomía , Infliximab/uso terapéutico
2.
Dig Dis Sci ; 69(4): 1389-1402, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38358458

RESUMEN

BACKGROUND: Ulcerative proctitis (UP), though associated with high symptom burden and poor quality of life, is excluded from most of the randomized controlled trials in UC, including the OCTAVE trials. We aimed to analyse the effectiveness of tofacitinib in UP, and compare it to that in left sided colitis (LSC) and pancolitis (PC). METHODS: This was a prospective cohort study. Patients with either steroid-dependent or refractory ulcerative colitis, who received tofacitinib, were divided into three groups based on the disease extent [UP, LSC and PC]. The primary outcome was comparison of proportion of patients in clinical remission in the three groups, at weeks 8, 16 and 48. Safety outcomes were reported using incidence rate per patient year of exposure. RESULTS: Clinical remission was achieved in 47%(15/32), 24%(23/94), and 43%(23/54) of patients at week 8, 56%(18/32), 37%(35/94), and 56%(30/54) of patients at week 16, and 59%(19/32), 38%(36/94), and 24%(13/54) of patients at week 48 in groups UP, LSC and PC, respectively. Corticosteroid-free clinical remission rates were significantly higher in patients in groups UP at week 48. Five (15%) patients with UP were primary non-responders to tofacitinib at week 16, while three (9%) patients had secondary loss of response at week 48. The probability of sustained clinical response was highest in patients with UP. Patients with UP had the lowest incidence of adverse effects. CONCLUSION: The effectiveness of tofacitinib in inducing and maintaining clinical remission is greater in patients with UP compared to LSC and PC.


Asunto(s)
Colitis Ulcerosa , Piperidinas , Proctitis , Pirimidinas , Humanos , Colitis Ulcerosa/epidemiología , Calidad de Vida , Estudios Prospectivos
3.
Dig Dis Sci ; 69(3): 775-790, 2024 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-38282185

RESUMEN

BACKGROUND: Patients with Inflammatory bowel disease (IBD) are susceptible to psychiatric co-morbidities. We aimed to ascertain the burden of anxiety, depression, and perceived stress in patients with IBD from north India. METHODS: Consenting adult patients with an established diagnosis of IBD were enrolled. The enrolled patients filled the Hospital Anxiety and Depression Scale (HADS) and Perceived Stress Scale (PSS) questionnaires. The patient and disease characteristics were analyzed to determine the correlations and predictors of psychiatric comorbidities. RESULTS: A total of 318 patients (255 UC, 63 CD; mean age 40.13 ± 12.06 years, 168 [52.8%] males; mean partial Mayo score 2.10 ± 2.35; and mean HBI 2.77 ± 2.13) were enrolled. The prevalence of anxiety, depression and moderate to high perceived stress was 14%, 12%, and 41%, respectively. Females had higher mean perceived stress, anxiety and depression scores compared to males. The partial Mayo score (PMS) correlated poorly with anxiety (ρ = 0.083, p = 0.187), depression (ρ = 0.123, p = 0.49) and perceived stress (ρ = 0.169; p = 0.007). The Harvey Bradshaw index (HBI) correlated fairly with anxiety (ρ = 0.336, p = 0.007) and poorly with depression (ρ = 0.287, p = 0.022) and perceived stress (ρ = 0.20; p = 0.117). Younger age (OR 0.93, 95% CI 0.90-0.97; p = 0.001) and hand-grip strength (OR 4.63, 95% CI 1.88-11.42; p = 0.001) predicted anxiety in patients with UC while rural area of residence (OR 4.75, 95% CI 1.03-21.98; p = 0.046) and HBI (OR 1.60, 95% CI 1.12-2.29; p = 0.009) were significant predictors of anxiety in patients with CD. CONCLUSION: Psychiatric comorbidities are common in patients with IBD, with higher prevalence in females. Young adults with UC and sarcopenia; and individuals with active CD living in rural areas are at an increased risk of anxiety.


Asunto(s)
Colitis Ulcerosa , Enfermedad de Crohn , Enfermedades Inflamatorias del Intestino , Pruebas Psicológicas , Autoinforme , Masculino , Adulto Joven , Femenino , Humanos , Adulto , Persona de Mediana Edad , Enfermedad de Crohn/diagnóstico , Colitis Ulcerosa/diagnóstico , Estudios de Cohortes , Depresión/diagnóstico , Depresión/epidemiología , Enfermedades Inflamatorias del Intestino/diagnóstico , Ansiedad/epidemiología , Ansiedad/etiología , Estrés Psicológico/diagnóstico , Estrés Psicológico/epidemiología , Índice de Severidad de la Enfermedad
4.
Nephrology (Carlton) ; 2024 Jul 18.
Artículo en Inglés | MEDLINE | ID: mdl-39022890

RESUMEN

Depletion of veins for dialysis access is a challenging life threatening situation for patients in need of haemodialysis. The utilisation of intracardiac catheter is a rare procedure with scarce reported experience. We describe the case of a 68-year-old male that contributes to the limited knowledge of performing a life-saving intracardiac catheter placement for emergency haemodialysis in a patient without immediate alternative renal replacement therapy available. We also retrospectively analyse the experience reported so far and summarise complications and outcomes. In our case, the patient was able to pursue haemodialysis after intracardiac catheter placement without any complications. Two weeks later, the patient successfully received a kidney transplant from a deceased donor and has a serum creatinine of 1.7 mg/dL after 2 years of follow-up. There are only four reported cases of kidney transplantation after the procedure, including our own. Intracardiac catheter is an emerging option that could be considered in certain patients as the last resort. Further investigation with regards to patient candidacy and procedure security are necessary.

5.
Clin Infect Dis ; 76(3): e526-e529, 2023 02 08.
Artículo en Inglés | MEDLINE | ID: mdl-35737946

RESUMEN

We enrolled 7 individuals with recurrent symptoms or antigen test conversion following nirmatrelvir-ritonavir treatment. High viral loads (median 6.1 log10 copies/mL) were detected after rebound for a median of 17 days after initial diagnosis. Three had culturable virus for up to 16 days after initial diagnosis. No known resistance-associated mutations were identified.


Asunto(s)
COVID-19 , Humanos , Tratamiento Farmacológico de COVID-19 , Ritonavir/uso terapéutico , Mutación
6.
Dig Dis Sci ; 68(2): 580-595, 2023 02.
Artículo en Inglés | MEDLINE | ID: mdl-36064826

RESUMEN

BACKGROUND: Inflammatory bowel disease (IBD) is associated with an increased risk of malnutrition and sarcopenia. AIMS: To evaluate the nutritional status of patients with IBD and determine the threshold values of different parameters of nutritional assessment to identify malnutrition. METHODS: This was a single-centre cross-sectional analysis of adult patients with IBD [ulcerative colitis (UC) and Crohn's disease (CD)] who underwent anthropometry [body mass index (BMI), mid upper arm circumference (MUAC) and triceps-fold thickness (TSF)], body composition analysis and assessment for sarcopenia [hand-grip strength and skeletal muscle index (SMI) at L3 vertebral level)]. Age- and gender-matched healthy adults served as controls. Malnutrition was defined according to the European Society of Clinical Nutrition and Metabolism (ESPEN) criteria. RESULTS: A total of 406 patients [336 (82.76%) UC and 70 (17.24%) CD; mean age 40.56 ± 13.67 years; 215 (52.95%) males] with IBD and 100 healthy controls (mean age 38.69 ± 10.90 years; 56 (56%) males) were enrolled. The mean BMI, MUAC, TSF thickness, fat and lean mass, hand-grip strength, and SMI at L3 vertebral level were lower in patients with IBD compared to controls. The prevalence of malnutrition was similar in UC and CD [24.40% (n = 82) and 28.57% (n = 20), respectively (p = 0.46)]. Thresholds for fat mass in females (15.8 kg) and visceral fat index in males (0.26) were both sensitive and specific to detect malnutrition. The cutoff values of MUAC and TSF thickness to identify malnutrition were 23.25 cm and 25.25 cm, and 16.50 mm and 8.50 mm, in females and males, respectively. CONCLUSION: Malnutrition and sarcopenia were common in patients with IBD, with the prevalence being similar in patients with both UC and CD.


Asunto(s)
Colitis Ulcerosa , Enfermedad de Crohn , Enfermedades Inflamatorias del Intestino , Desnutrición , Sarcopenia , Adulto , Masculino , Femenino , Humanos , Persona de Mediana Edad , Enfermedad de Crohn/complicaciones , Colitis Ulcerosa/complicaciones , Estudios Transversales , Prevalencia , Desnutrición/diagnóstico , Estado Nutricional , Enfermedades Inflamatorias del Intestino/complicaciones
8.
J Gastroenterol Hepatol ; 35(3): 418-424, 2020 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-31408913

RESUMEN

BACKGROUND AND AIM: Fecal microbiota transplantation (FMT) targets gut microbiome dysbiosis and is an emerging therapy for ulcerative colitis (UC). Although initial results with FMT in patients with active UC are encouraging, data regarding its acceptability, tolerability, and safety are scant. METHODS: A retrospective analysis of patients with active UC (Mayo clinic score ≥ 4), who received multisession FMT (at weeks 0, 2, 6, 10, 14, 18, and 22) via colonoscopy between June 2016 and June 2018, was performed. Patient acceptability, tolerability, and immediate and long-term safety of the therapy were assessed. RESULTS: Of the 129 patients with active UC who were offered FMT, 101 patients consented, giving acceptability of 78.3%. Fecal slurry retention time improved with each session (3.27 ± 1.06 h for the first session vs 5.12 ± 0.5 h for the seventh session). Abdominal discomfort, flatulence, abdominal distension, borborygmi, and low-grade fever (30.8%, 15.9%, 9.8%, 7.9%, and 7.6%, respectively) were the most common post-procedural short-term adverse events. Long-term adverse events included new-onset urticaria (n = 2, 4.3%), arthritis/arthralgia (n = 3, 6.5%), depression (n = 1, 2.2%), partial sensorineural hearing loss (n = 1, 2.2%), and allergic bronchitis (n = 1, 2.2%). Thirteen (12.9%) patients dropped out because of adverse events. CONCLUSION: Fecal microbiota transplantation appears to be a safe and well-tolerated procedure, with good acceptability in patients with active UC.


Asunto(s)
Colitis Ulcerosa/terapia , Trasplante de Microbiota Fecal , Adulto , Trasplante de Microbiota Fecal/efectos adversos , Femenino , Humanos , Masculino , Estudios Retrospectivos , Seguridad , Resultado del Tratamiento , Adulto Joven
9.
Bioorg Chem ; 94: 103436, 2020 01.
Artículo en Inglés | MEDLINE | ID: mdl-31761410

RESUMEN

Indoline framework is often perpended as a privileged heterocycle present in medicinally valuable compounds of natural and synthetic origin. This review article presents the rational approaches/strategies employed for the design of anticancer indolines along with the structure activity relationship and mechanistic insights revealed in the in-vitro and in-vivo assays. The chemist has always been fascinated towards the indoline ring for the construction of antitumor scaffolds owing to its versatility as evidenced by its existence in scaffolds inducing antiproliferative effects via diverse mechanisms. To the delight of medicinal chemist, the applicability of indoline has also been expanded towards the design of dual inhibitors (multitargeting anticancer agents) as well as PROTACS. Overall, it can be concluded that indoline moiety is a magic bullet and the scaffolds containing this ring are foraying towards detailed preclinical and clinical stage investigations by leaps and bounds.


Asunto(s)
Antineoplásicos/farmacología , Descubrimiento de Drogas , Indoles/farmacología , Neoplasias/tratamiento farmacológico , Antineoplásicos/química , Proliferación Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Ensayos de Selección de Medicamentos Antitumorales , Humanos , Indoles/química , Estructura Molecular , Neoplasias/patología , Relación Estructura-Actividad
10.
J Dairy Sci ; 103(8): 6894-6899, 2020 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-32534919

RESUMEN

This study aimed to compare the thermal resistance of Salmonella Senftenberg 775 W with other serovars of Salmonella in nonfat dry milk (NDM) and hydrated NDM. The scientific literature suggests that Salmonella Senftenberg 775 W is the most heat-resistant serovar in high-water-activity foods such as milk, but little is known about the heat resistance of Salmonella Senftenberg 775 W compared with other Salmonella serovars in low-water-activity foods such as NDM. The 5 serovars of Salmonella used in this study were Enteritidis, Montevideo, Newport, Senftenberg, and Typhimurium. The hydration of NDM was conducted at 13% (wt/vol) total solids. The NDM was inoculated with the 5 individual serovars of Salmonella and dried again to its original pre-inoculation water activity. Hydrated NDM was prepared from individually inoculated NDM. The surviving Salmonella population at predetermined time-temperature intervals were enumerated using injury-recovery medium, and the average log reductions for the individual serovars were calculated. As expected, Salmonella Senftenberg 775 W was the most heat-resistant serovar in hydrated NDM at 59°C and 65°C. However, the heat resistance of Salmonella Senftenberg 775 W was found to be lower than or comparable to that of other serovars in low-water-activity NDM at 80°C and 90°C.


Asunto(s)
Productos Lácteos/microbiología , Microbiología de Alimentos , Calor , Leche/microbiología , Salmonella/aislamiento & purificación , Animales , Polvos , Serogrupo
11.
13.
J Gastroenterol Hepatol ; 33(4): 926-933, 2018 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-28921677

RESUMEN

BACKGROUND AND AIM: The epidemiology and clinical profile of hepatitis C virus (HCV) varies worldwide, and data from developing countries are sparse. The aim of the present study was to assess the clinical profile of HCV infection in a developing country in South-East Asia (India). METHODS: This observational study assessed patient demographics, viral characteristics, risk factors for virus acquisition, and disease characteristics in HCV patients diagnosed between January 2004 and December 2015. RESULTS: Of 8035 patients who were diagnosed with HCV infection, a majority were men (68.3%), middle aged (52.2%), and from low (34%) to middle (46%) socioeconomic status and rural population (69.8%). Eighty-two percent had identifiable risk factors, the most common being history of dental treatment (52%) and therapeutic injections with reusable syringes/needles (45%). Household contacts of index patients had high prevalence of HCV (15.3%). Common genotypes were genotype 3 (70.4%) and genotype 1 (19.3%). Although a majority of patients were either asymptomatic (54.8%) or had non-specific symptoms (6.7%) at presentation, a significant proportion (9.3%) had advanced liver disease. Presentation with cirrhosis (38.8%) was associated with male gender, higher age at time of virus detection, rural residence, alcohol or opium intake, and coinfections with hepatitis B virus or human immunodeficiency virus. CONCLUSIONS: Hepatitis C virus infection in northern India is seen more commonly in men, the middle aged and people from rural background and low to middle socioeconomic status. The common possible risk factors are dental treatment and exposure to reused syringes and needles. Although the most common presentation is incidental detection, a large number of patients present with advanced liver disease.


Asunto(s)
Hepatitis C/epidemiología , Hepatitis C/etiología , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Atención Odontológica/efectos adversos , Femenino , Hepatitis C/transmisión , Humanos , India/epidemiología , Masculino , Persona de Mediana Edad , Compartición de Agujas/efectos adversos , Prevalencia , Factores de Riesgo , Población Rural , Factores Sexuales , Clase Social , Adulto Joven
14.
Niger Postgrad Med J ; 23(4): 227-231, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-28000645

RESUMEN

BACKGROUND: The community-based dental outreach programs play a very crucial role in declining discovery-delivery disconnect by introducing awareness through health education and dental adumbrating services to the community members. However, the success of any oral health programme depends largely on how it meets the needs and expectations of the target community. Therefore, the present study was designed for the assessment of patient satisfaction at various rural outreach dental camps conducted over a period of 2 months. MATERIALS AND METHODS: The present study was conducted on patients visiting weekly and monthly outreach dental programmes organised by the Department of Public Health Dentistry. Data were obtained from a total of 298 patients using a pre-tested questionnaire as a survey instrument. The questionnaire consisted of nine questions, measuring the patient satisfaction levels on a five-point Likert scale. RESULTS: The highest mean satisfaction score (4.97 ± 0.59) was observed for the question on the overall performance of camp, whereas waiting time for treatment, quality of the treatment and explanation of need for referral exhibited lowest mean scores. The mean satisfaction scores for the monthly camp (4.55 ± 0.52) were significantly higher as compared to the weekly camps (4.38 ± 0.55) (P = 0.013). CONCLUSION: The results of the study showed that the patient satisfaction scores were satisfactory to good for various aspects of the weekly and monthly dental outreach programmes. Such programmes should be conducted on regular basis, and comprehensive oral care should be provided.


Asunto(s)
Atención Odontológica , Satisfacción del Paciente , Humanos , India , Nigeria , Satisfacción Personal , Población Rural , Encuestas y Cuestionarios
15.
Curr Gastroenterol Rep ; 16(11): 418, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-25277043

RESUMEN

Both intestinal tuberculosis and Crohn's disease are chronic granulomatous inflammatory diseases of the bowel having overlap of clinical, endoscopic, radiological, and histological features. Differentiating between the two disorders is relevant not only in Asian countries but also in the West. In spite of diagnostic criteria for both diseases being available, still the dilemma of segregating the two diseases remains. Nearly one third of the patients with Crohn's disease may receive anti-tuberculosis treatment also. Diagnosis should be based on the combination of all disease-specific and corroborative evidences.


Asunto(s)
Enfermedad de Crohn/diagnóstico , Enfermedades del Íleon/diagnóstico , Tuberculosis Gastrointestinal/diagnóstico , Biomarcadores/sangre , Diagnóstico Diferencial , Endoscopía Gastrointestinal/métodos , Humanos , Prueba de Tuberculina
16.
Trop Gastroenterol ; 35 Suppl 1: S29-34, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-25735124

RESUMEN

Biologicals have a well established role as rescue therapy in management of steroid refractory cases of Ulcerative colitis and Crohn's disease. However, high cost and potential risk of infections like tuberculosis limits their use in developing countries. As there is paucity of data on the use of various biological agents from developing countries like India, we are reporting the limited Indian experience with the available agents. Infliximab has been used as a rescue therapy for severe refractory Ulcerative colitis while other agents have been used as a part of multicentre clinical trials.


Asunto(s)
Terapia Biológica/métodos , Colitis Ulcerosa/tratamiento farmacológico , Fármacos Gastrointestinales/uso terapéutico , Enfermedad Aguda , Anticuerpos Monoclonales/uso terapéutico , Anticuerpos Monoclonales Humanizados/uso terapéutico , Basiliximab , Humanos , India , Infliximab , Proteínas Recombinantes de Fusión/uso terapéutico
17.
Cureus ; 16(2): e53697, 2024 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-38455771

RESUMEN

A 59-year-old male with a history of alcohol abuse presented with altered mental status. Upon examination, he was hypertensive and lethargic, and laboratory results revealed severe transaminitis, coagulopathy, and lactic acidosis, despite having normal serum alcohol levels. Additionally, his urine drug screen tested positive for methamphetamine. Following the exclusion of infectious, autoimmune, and other common causes of acute hepatitis, a diagnosis of methamphetamine-induced acute hepatitis was established. A non-acetaminophen toxicity N-acetylcysteine (NAC) protocol was initiated, resulting in a positive response with improvement in mentation and a decrease in liver enzyme levels. This case emphasizes the potential effectiveness of NAC in treating amphetamine-induced liver injury, supported by the limited available literature on the subject.

18.
Indian J Gastroenterol ; 43(1): 129-144, 2024 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-38334893

RESUMEN

Fecal microbiota transplantation (FMT) has emerged as a promising therapeutic modality within the domain of inflammatory bowel disease (IBD). While FMT has secured approval and demonstrated efficacy in addressing recurrent and refractory Clostridioides difficile infection, its application in IBD remains an area of active exploration and research. The current status of FMT in IBD reflects a nuanced landscape, with ongoing investigations delving into its effectiveness, safety and optimal implementation. Early-stage clinical trials and observational studies have provided insights into the potential of FMT to modulate the dysbiotic gut microbiota associated with IBD, aiming to mitigate inflammation and promote mucosal healing. However, considerable complexities persist, including variations in donor selection, treatment protocols and outcome assessments. Challenges in standardizing FMT protocols for IBD treatment are compounded by the dynamic nature of the gut microbiome and the heterogeneity of IBD itself. Despite these challenges, enthusiasm for FMT in IBD emanates from its capacity to address gut microbial dysbiosis, signifying a paradigm shift towards more comprehensive approaches in IBD management. As ongoing research progresses, an enhanced understanding of FMT's role in IBD therapy is anticipated. This article synthesizes the current status of FMT in IBD, elucidating the attendant challenges and aspiring towards the refinement of its application for improved patient outcomes.


Asunto(s)
Infecciones por Clostridium , Enfermedades Inflamatorias del Intestino , Humanos , Trasplante de Microbiota Fecal/métodos , Enfermedades Inflamatorias del Intestino/terapia , Enfermedades Inflamatorias del Intestino/complicaciones , Infecciones por Clostridium/terapia , Infecciones por Clostridium/complicaciones , Estudios Longitudinales , Inflamación/complicaciones , Disbiosis/terapia , Resultado del Tratamiento
19.
RSC Med Chem ; 15(6): 1849-1876, 2024 Jun 19.
Artículo en Inglés | MEDLINE | ID: mdl-38911168

RESUMEN

Hyperuricemia is characterized by higher-than-normal levels of uric acid in the bloodstream. This condition can increase the likelihood of developing gout, a form of arthritis triggered by the deposition of urate crystals in the joints, leading to inflammation and pain. An essential part of purine metabolism is played by the enzyme xanthine oxidase (XO), which transforms xanthine and hypoxanthine into uric acid. Despite its vital role, diseases such as gout have been associated with elevated uric acid levels, which are linked to increased XO activity. To manage hyperuricemia, this study focuses on potential nitrogen based heterocyclic compounds that may serve as XO inhibitors which may lower uric acid levels and prevent hyperuricemia. Xanthine oxidase inhibitors are a class of medications used to treat conditions like gout by reducing the production of uric acid. The present study demonstrates numerous compounds, particularly nitrogen containing heterocyclic compounds including their synthesis, structure-activity relationship, and molecular docking studies. This paper also contains drugs undergoing clinical studies and the xanthine oxidase inhibitors that have been approved by the FDA.

20.
J Food Prot ; 87(6): 100280, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38642807

RESUMEN

A validation study was conducted to investigate the effect of the English muffin baking process to control Salmonella contamination and to study the thermal inactivation kinetic parameters (D- and z-values) of Salmonella in English muffin dough. The unbleached bread flour was inoculated with 3 serovar Salmonella cocktail (Salmonella serovars viz., Newport, Typhimurium, and Senftenberg), and dried back to its preinoculated water activity levels with 7.46 ± 0.12 log CFU/g of Salmonella concentration. The Salmonella inoculated flour was used to prepare English muffin batter and baked at 204.4°C (400°F) for 18 min and allowed to cool at ambient air for 15 min. The English muffins reached 99 ± 0°C (211.96 ± 0.37°F) as their maximum mean internal temperature during baking. The pH and aw of English muffin dough were 5.01 ± 0.01 and 0.947 ± 0.003, respectively. At the end of the 18-min baking period, the Salmonella inoculated English muffins recorded a more than 5 log CFU/g reduction on the injury-recovery media. The D-values of 3 serovar cocktails of Salmonella at 55, 58.5, and 62°C were 42.0 ± 5.68, 15.6 ± 0.73, and 3.0 ± 0.32 min, respectively; and the z-value was 6.2 ± 0.59°C. The water activity (aw) of the English muffin crumb (0.947 ± 0.003 to 0.9557 ± 0.001) remained statistically unchanged during baking, whereas the aw of the muffin crust decreased significantly (0.947 ± 0.003 to 0.918 ± 0.002) by the end of 18 min of baking. This study validates and documents the first scientific evidence that baking English muffins at 204.4°C (400°F) for 18 min acts as an effective kill step by controlling Salmonella population by >5 log CFU/g.


Asunto(s)
Recuento de Colonia Microbiana , Contaminación de Alimentos , Microbiología de Alimentos , Salmonella , Contaminación de Alimentos/prevención & control , Contaminación de Alimentos/análisis , Pan/microbiología , Humanos , Manipulación de Alimentos/métodos , Culinaria , Harina/microbiología , Cinética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA